Shanghai Fosun Pharmaceutical (Group) Co.,Ltd（Fosun Pharma, or the Company）. announced that the Company has completed the issuance of the first tranche of corporate bonds on 4 March 2016 in a principle amount of RMB1.5 billion, which can be over-allotted for up to another RMB1.5 billion. The development prospect of Fosun Pharma has been generally recognized by investors and the Bonds will ultimately raise RMB3 billion in total with a coupon rate at 3.35%. According to its announcement, the Bonds has a term of five years with the issuer’s option to raise the coupon rate after the end of the third year and the investors’ entitlement to sell back the Bonds. The proceeds from the issuance of the Bonds are mainly to be used for the Company to optimize debt structure and to replenish the general working capital.

The Bonds has received “AAA” rating and the corporate credit rating is “AAA”.

Established in 1994, Fosun Pharma (stock code: 600196-SH, 02196-HK) is a leading healthcare group in the PRC.

Fosun Pharma strategically covers important segments of the healthcare industry value-chain, including research and development, pharmaceutical manufacturing, medical diagnosis, medical devices, pharmaceutical distribution and retail, and healthcare services, making contribution to improving public health. Fosun Pharma maintains a National Recognized Enterprise Technology Centre and a highly capable international R&D team, focusing on innovation and research of therapeutic areas including cardiovascular system, metabolism and digestive tract system, central nervous system, blood system, anti-tumor and anti-infection diseases.

With its commitment to Innovation for Good Health and creating a better future, Fosun Pharma will continue insisting on the strategic development approach of “organic growth with external expansion and integrated business operation”. The Company strives to be one of the first-class enterprises in the global healthcare market.